Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

6-Hydroxymethylacylfulvene (MGI-114) is a semisynthetic analogue of the toxin illudin S, a product of the Omphalotus mushroom. MGI-114 induces cytotoxicity in a variety of solid tumors in vivo, including the refractory HT29 human colon cancer xenograft. In this study, the potential application of MGI-114 in the treatment of colon cancer was further explored by evaluating the activity of MGI-114 in combination with irinotecan (CPT-11) and 5-fluorouracil (5FU). Groups of 9 nude mice bearing HT29 xenografts were treated with either single agent MGI-114, CPT-11, or 5FU, or MGI-114 in combination with CPT-11 or 5FU. MGI-114 was administered at doses of 3.5 and 7 mg/kg i.p. daily on days 1 through 5, and CPT-11 and 5FU were administered at doses of 50 and 100 mg/kg i.p. on days 1, 12, and 19. In the single agent studies, MGI-114, CPT-11, and 5FU all resulted in decreased final tumor weights compared with vehicle-treated controls (P<0.05), but only MGI-114 at 7 mg/kg produced partial responses. When MGI-114 at 3.5 mg/kg was combined with CPT-11, significant decrements in final tumor weights occurred compared with monotherapy with the same doses of MGI-114 and CPT-11 (P< or =0.001). Also, administration of the low-dose combination (MGI-114 at 35 mg/kg and CPT-11 at 50 mg/kg) resulted in final tumor weights similar to those achieved after administration of high-dose MGI-114 as a single agent. Moreover, the combination of MGI-114 and CPT-11 produced partial responses in nearly all of the animals, with some animals achieving complete responses. The outcome with the combination of MGI-114 and 5FU was less striking, with fewer partial responses and no complete responses. These results suggest enhanced activity when MGI-114 is combined with CPT-11, and clinical trials to further evaluate this combination regimen are planned.

[1]  T. Mcmorris,et al.  Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. , 1990, Journal of the National Cancer Institute.

[2]  D. Cox,et al.  An Analysis of Transformations , 1964 .

[3]  Melinda G. Hollingshead,et al.  Human Tumor Xenograft Models in NCI Drug Development , 1997 .

[4]  S. Pilotti,et al.  Role of apoptotic response in cellular resistance to cytotoxic agents. , 1997, Pharmacology & therapeutics.

[5]  J L MADDEN,et al.  CANCER OF THE COLON. , 1964, American journal of surgery.

[6]  K. Kohn,et al.  Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. , 1996, Cancer research.

[7]  M. Duguet,et al.  When helicase and topoisomerase meet! , 1997, Journal of cell science.

[8]  U. Eppenberger,et al.  The dual role of mutant p53 protein in chemosensitivity of human cancers. , 1996, Anticancer research.

[9]  K W Kohn,et al.  Cell cycle control and cancer chemotherapy , 1994, Journal of cellular biochemistry.

[10]  D. Troyer,et al.  Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). , 1997, Biochemical pharmacology.

[11]  K. Kohn,et al.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.

[12]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[13]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[14]  T. Mcmorris,et al.  In vitro and in vivo studies on the anticancer activity of dehydroilludin M. , 1995, Anticancer research.

[15]  M. Rothenberg.  Topoisomerase I inhibitors: review and update. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Mcmorris,et al.  (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. , 1996, Journal of natural products.

[17]  W. T. Beck,et al.  Preclinical evaluation of illudins as anticancer agents. , 1987, Cancer research.

[18]  E. Raymond,et al.  Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers , 1997, Anti-cancer drugs.

[19]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Liu,et al.  The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.

[21]  M. Montoya,et al.  Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. , 1994, Biochemical pharmacology.

[22]  H. M. Geller,et al.  Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity , 1996, The Journal of cell biology.

[23]  Y. Pommier,et al.  Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.

[24]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[25]  J DeMiguel,et al.  Cancer of the colon , 1973 .

[26]  D. V. Von Hoff,et al.  Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. , 1997, Cancer research.

[27]  Y. Pommier,et al.  The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. , 1995, Leukemia.

[28]  M. Montoya,et al.  Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. , 1995, Cancer research.